Upadacitinib induction and maintenance therapy were associated with higher rates of normalisation of health-related quality-of-life (HRQoL) than placebo.
Tulisokibart displayed durable improvements in clinical and endoscopic outcomes in patients with moderately to severely active ulcerative colitis.
Perianal fistulising Crohn’s disease was associated with increased IFN-γ expression and response in fistula tracts and luminal mucosa.
Data from the cirrhosis subpopulation in the ZENITH-CKD trial suggest that the zibotentan and dapagliflozin combination may benefit liver health.
Cendakimab outperformed placebo in patients with eosinophilic oesophagitis (EoE) across various efficacy endpoints in a phase 3 study.
Tradipitant successfully reduced nausea and vomiting associated with motion sickness in a clinical trial. Both low dose and high doses were well-tolerated.
Fluorescence confocal laser microscopy may allow real-time tissue diagnosis from solid pancreatic lesions, via an endoscopic ultrasound procedure.
Partially hydrolysed guar gum (PHGG) appeared to be efficacious in patients with irritable bowel syndrome-associated chronic constipation.
A 66-year-old patient enters the ER with persistent fever, night sweats and significant weight loss. He is admitted with the diagnosis of “persistent bronchopneumonia”...
An accelerated treatment algorithm appeared to benefit patients with large pancreatic WON in terms of length-of-stay in the hospital and major complications.
A study found faecal microbiota transplantation was safe and non-inferior to vancomycin in patients with primary Clostridioides difficile infections.
Etrasimod was associated with favourable outcomes and tolerability in patients with moderately to severely active CD in a phase 2 trial extension.
Key issues were discussed at the UEG Week related to current approaches to diagnostics, treatment and practical takeaways of malabsorption syndromes.
A special congres session took a critical look at common errors in the management of lower gastrointestinal conditions, providing insights for clinical practice.
Hepatobiliary and disease guidelines and updates were discussed during a session on prancreas-related cancer, exocrine insufficiency, cysts, and NASH.
A meta-analysis showed that HS familial cases are associated with higher cardiovascular diseases, hyperlipidaemia, and diabetes mellitus risk.
Post-hoc analysis of the THRIVE-AA1 and THRIVE-AA2 trials showed satisfaction in the THRIVE-AA1 and THRIVE-AA2 trials as early as week 12.
Povorcitinib led to a sustained reduction of pruritus and skin lesions in prurigo nodularis in a randomised-controlled phase 2 study.
Continuing bimekizumab for 2 years led to maintenance of various HiSCR and International Hidradenitis Suppurativa Severity Score System (IHS4) scores.
Orismilast demonstrated higher rates of Investigator Global Assessment of 0/1 at week 16 compared with placebo in the phase 2b ADESOS trial.